Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tiziana Life Sciences
Company Location: LONDON, ENGLAND X0 SW1Y 4LB
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TILS-020 | P2 |
Not yet recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2024-12-01 |
57% |